508 citations
,
June 2009 in “Current drug metabolism” This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.
88 citations
,
August 2019 in “Frontiers in immunology” This review discusses the role of tyrosine kinase signaling pathways in autoimmune and inflammatory skin diseases and reports no new clinical results, highlighting ongoing research into small-molecule tyrosine kinase inhibitors as potential treatments.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
32 citations
,
September 2015 in “Dermatology” This study describes a newly recognized skin reaction associated with dasatinib, nilotinib, and ponatinib, marked by a lichenoid exanthem with severe pruritus that may necessitate discontinuation of therapy.
25 citations
,
November 2013 in “Journal of the American Academy of Dermatology” This study observed that 71% of chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors experienced adverse cutaneous reactions, which were generally less severe than those caused by imatinib.